Published in Cancer Weekly, June 8th, 2004
In connection with the financing, the company issued 2.9 million shares of common stock at a price of $5.25. Granite Financial Group, Inc., acted as the placement agent for the financing.
Sonus expects to use proceeds of the sale primarily for the continuing advancement of its lead product candidate, Tocosol Paclitaxel, currently in phase IIb clinical trials, as well as to accelerate the preclinical development of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.